Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation - Wikidata - awgldk - TriplyDB

Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation

Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation

http://www.wikidata.org/entity/Q34405101

about

Hypoglycemic agents and potential anti-inflammatory activity Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1 Pathophysiological mechanisms involved in non-alcoholic steatohepatitis and novel potential therapeutic targets Changes in the Intestinal Microbiome and Alcoholic and Nonalcoholic Liver Diseases: Causes or Effects?The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities.Extrapancreatic effects of incretin hormones: evidence for weight-independent changes in morphological aspects and oxidative status in insulin-sensitive organs of the obese nondiabetic Zucker rat (ZFR).Transfer factor for carbon monoxide in patients with COPD and diabetes: results from the German COSYCONET cohort Nutrition, inflammation and liver-spleen axis.Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies.Effects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling.Self-reported eating speed in relation to non-alcoholic fatty liver disease in adults.Effects of antidiabetic drugs on epicardial fat

P2860

Q26750414-CCEC28BE-FD6D-422D-8877-71A72FBBABBE Q26750746-8257394B-2106-49FC-8E35-C10946C28181 Q26752511-502C1D69-A4D1-489E-848D-E500EA189CB4 Q35668745-27050F33-DF7F-49EF-A2D4-480A5E0AB27B Q35947349-91351976-49DE-4A98-A88F-65030A05AC66 Q37024780-0DDD1DB0-4E03-4C0D-9285-037D256BC94F Q37176743-3481CA0D-5FE0-4AA8-BF9E-2B940F3BCF5B Q37586590-4AEF1BE5-EB0D-4C65-A178-D3F62A9751FA Q40086170-5BDDB3C8-5EF2-4487-A6C1-A616F38ED638 Q42206856-E7ECAC6A-7C37-4B24-B5AC-825ED445E3FE Q47899237-1985DE3A-F0B8-4FD4-85DC-1FD399997265 Q50962958-C5213168-E3D8-4E46-86AC-E675154590C8 Q58737177-66EDF4E0-F7FB-48CD-B5D3-22A957E60980

P2860

Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation

http://www.wikidata.org/entity/Q34405101

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Effects of glucagon-like pepti ...... liver disease and inflammation

@ast

Effects of glucagon-like pepti ...... liver disease and inflammation

@en

Effects of glucagon-like pepti ...... liver disease and inflammation

@nl

type

label

Effects of glucagon-like pepti ...... liver disease and inflammation

@ast

Effects of glucagon-like pepti ...... liver disease and inflammation

@en

Effects of glucagon-like pepti ...... liver disease and inflammation

@nl

prefLabel

Effects of glucagon-like pepti ...... liver disease and inflammation

@ast

Effects of glucagon-like pepti ...... liver disease and inflammation

@en

Effects of glucagon-like pepti ...... liver disease and inflammation

@nl

P1433

Q34405101-B895CD03-6F78-4FD5-8FCF-307D7BFFC310

P1476

Q34405101-C83D649D-780B-4E74-8D40-2049CCB96637

P2093

Q34405101-0F644AF5-C9F9-4BC4-B4D0-253FD8664DA9

Q34405101-3D37EEE6-8897-4D34-AAA7-272ED2123591

Q34405101-5CA44900-2938-4CC6-B79C-215DF016C65C

Q34405101-D1962A02-00A7-4BE3-8163-6814B80C0436

P2860

Q34405101-043AAE2D-4D95-426E-A41A-199D07EB6A2E

Q34405101-06B8E39A-5087-491A-91FD-4CA75AD521DD

Q34405101-1155478B-A241-472F-8B2B-DB7CCAFCDF7C

Q34405101-16E0043A-9493-42B3-B54D-61D93F33FA65

Q34405101-1D996FD7-A9D9-4F4C-B186-5135C692DECD

Q34405101-1F165243-C514-4C36-BE10-65FF1749F07D

Q34405101-2018250F-B6EB-4C10-8A8B-5ACA15ADB843

Q34405101-213A8FCD-C1B1-4301-9502-582F4A581225

Q34405101-278A5193-3D27-45C8-AB4B-812C69CA1076

Q34405101-2880ABAE-ADDB-4ECA-A224-23EA843B4058

P304

Q34405101-05C3B48A-8FEC-497C-81D3-DA3AECE74B78

P31

Q34405101-FEF9A6DA-93C1-4BB1-BA09-AACC37635B2A

P356

Q34405101-82531E27-598A-4DCE-B5DB-34268494C3BB

P407

Q34405101-84046AF2-7861-4FCA-9BA9-02D2A1BE63A8

P433

Q34405101-D1EBB950-1F1D-4851-BEB9-5F1D0F1E08DD

P478

Q34405101-2BD12566-76A8-48A6-BECE-D33E0347E786

P577

Q34405101-9A052962-BD61-47FE-836B-A6CB63F65A23

P5875

Q34405101-C88767D1-D121-4260-908D-139B5D7A76FD

P698

Q34405101-7944D50E-CBDF-47B2-8FC4-1DB45DA895B7

P932

Q34405101-F4059130-DAF4-40FF-80E6-D5912DB5976B

P356

WJG.V20.I40.14821

P1433

World Journal of Gastroenterology

P1476

Effects of glucagon-like pepti ...... liver disease and inflammation

@en

P2093

Aaron M Gusdon

http://www.w3.org/2001/XMLSchema#string

Huan Liu

http://www.w3.org/2001/XMLSchema#string

Shen Qu

http://www.w3.org/2001/XMLSchema#string

Xing-Chun Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

Mechanisms of action of glucagon-like peptide 1 in the pancreas

Incretin mimetics as a novel therapeutic option for hepatic steatosis

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Glucagon-like peptide-1 receptor agonist protects against hyperglycemia-induced cardiocytes injury by inhibiting high mobility group box 1 expression

MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity

Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes

Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled tr

The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial

P304

14821-14830

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V20.I40.14821

http://www.w3.org/2001/XMLSchema#string

P407

P433

40

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

267735461

http://www.w3.org/2001/XMLSchema#string

P698

25356042

http://www.w3.org/2001/XMLSchema#string

P932

4209545

http://www.w3.org/2001/XMLSchema#string